Biotalys: Patrick Van Beneden Departs from the Board After 13 Years
Patrick Van Beneden is leaving the board of the Belgian biotech company Biotalys, effective Tuesday, June 30, 2026. Serving as a non-executive director since the company's inception in 2013, he has guided the transformation of the startup into a publicly traded entity focused on sustainable agricultural innovations.
A Departure After Thirteen Years of Foundational Involvement
Patrick Van Beneden is stepping down from his role as a non-executive director of Biotalys with immediate effect. Having been with the company since its inception in 2013, he has led its evolution from a spin-off of the Flemish Institute of Biotechnology (VIB) to its IPO on Euronext Brussels. His affiliation with Gimv, the European investment vehicle and a key co-founder of Biotalys, enabled him to bring recognized expertise in life sciences and agricultural technologies.
The Board Maintains Continuity of Governance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Simon Moroney, chairman of the board, praised Van Beneden's thirteen years of strategic leadership and contributions to the company's growth. The board asserts its commitment to maintaining strong governance and a diversity of expertise following the departure, without specifying the details of replacement or any interim arrangements.
Biotalys intends to maintain a cost-conscious approach to fully exploit the potential of its unique technology platform
Risks mentioned
Limited financial runway of only until end of Q1 2027 requiring additional financing
Regulatory approval delays in U.S. and E.U. for EVOCA and EVOCA NG could impact commercialisation timeline
Dependence on successful manufacturing scale-up and partnerships to achieve commercial viability of lead products
Opportunities identified
Regulatory approval pathway for EVOCA NG in U.S. (2029 launch) and Europe (2030 launch) targeting USD 1.1 billion market
BioFun-6 lead candidate demonstrating strong efficacy in field trials across multiple crops and geographies
Strategic partnership with 21st.BIO for manufacturing efficiencies and commercially competitive cost structure
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
